BLPH — Bellerophon Therapeutics Share News
0.000.00%
Last trade - 00:00Bellerophon Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Bellerophon Therapeutics Inc expected to post a loss of 60 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-General Motors, Freshpet, Rivian, energy stocks
U.S. STOCKS ON THE MOVE-Rivian, Darden Restaurants, General Motors, FedEx
Brief: Bellerophon Reports Positive Top-Line Data From Phase 2 Acute Dose Escalation Study Of Inopulse For Treatment Of Pulmonary Hypertension Associated With Sarcoidosis
Bellerophon Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Bellerophon Provides Clinical Program Update And Reports Third Quarter 2021 Financial Results
Brief: Bellerophon Therapeutics Appointed Peter Fernandes As Interim Principal Executive Officer
Bellerophon Therapeutics Inc expected to post a loss of 63 cents a share - Earnings Preview
Bellerophon Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Bellerophon Provides Clinical Program Update And Reports Second Quarter 2021 Financial Results
Bellerophon Therapeutics Inc expected to post a loss of 66 cents a share - Earnings Preview
Bellerophon Therapeutics Inc expected to post a loss of 66 cents a share - Earnings Preview
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:38 AM
Brief: Bellerophon Appoints Naseem Amin, M.D. As Chairman Of Its Board Of Directors
Bellerophon Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Bellerophon Therapeutics Q1 Loss Per Share $0.58
Bellerophon Therapeutics Inc expected to post a loss of 71 cents a share - Earnings Preview
Brief: Bellerophon Therapeutics Inc Says Jonathan Peacock, Currently Chairman Of Board Notified Co That He Will Not Stand For Re-Election To Board